Prestige Consumer Healthcare (NYSE:PBH) Downgraded by ValuEngine

ValuEngine lowered shares of Prestige Consumer Healthcare (NYSE:PBH) from a sell rating to a strong sell rating in a report issued on Monday morning, ValuEngine reports.

Other equities analysts also recently issued reports about the company. Zacks Investment Research downgraded Hanger from a hold rating to a sell rating in a research report on Tuesday, May 28th. CIBC reiterated a hold rating and set a $84.00 target price on shares of Prestige Consumer Healthcare in a research report on Monday, May 27th. TheStreet downgraded USD Partners from a b- rating to a c+ rating in a research report on Friday, May 10th. Finally, Royal Bank of Canada reiterated a buy rating and set a $97.00 target price on shares of Prestige Consumer Healthcare in a research report on Friday, March 15th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the stock. The company presently has a consensus rating of Hold and an average target price of $57.77.

PBH stock opened at $30.97 on Monday. The stock has a market cap of $1.62 billion, a P/E ratio of 11.14, a P/E/G ratio of 1.80 and a beta of 0.93. Prestige Consumer Healthcare has a 1 year low of $26.25 and a 1 year high of $41.76. The company has a current ratio of 2.37, a quick ratio of 1.43 and a debt-to-equity ratio of 1.64. The business has a fifty day moving average price of $30.65.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, May 9th. The company reported $0.72 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.70 by $0.02. The firm had revenue of $241.03 million for the quarter, compared to the consensus estimate of $237.22 million. Prestige Consumer Healthcare had a positive return on equity of 12.45% and a negative net margin of 3.67%. The company’s revenue for the quarter was down 5.8% on a year-over-year basis. During the same period last year, the business posted $0.62 EPS. Sell-side analysts expect that Prestige Consumer Healthcare will post 2.81 earnings per share for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quadrant Capital Group LLC raised its holdings in Prestige Consumer Healthcare by 2,979.3% during the first quarter. Quadrant Capital Group LLC now owns 1,786 shares of the company’s stock valued at $53,000 after acquiring an additional 1,728 shares during the period. Geode Capital Management LLC raised its holdings in Prestige Consumer Healthcare by 6.5% during the fourth quarter. Geode Capital Management LLC now owns 566,529 shares of the company’s stock valued at $17,493,000 after acquiring an additional 34,514 shares during the period. Eagle Asset Management Inc. raised its holdings in Prestige Consumer Healthcare by 2.0% during the first quarter. Eagle Asset Management Inc. now owns 220,998 shares of the company’s stock valued at $6,610,000 after acquiring an additional 4,244 shares during the period. BlackRock Inc. raised its holdings in Prestige Consumer Healthcare by 4.0% during the fourth quarter. BlackRock Inc. now owns 6,457,359 shares of the company’s stock valued at $199,402,000 after acquiring an additional 248,243 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in Prestige Consumer Healthcare by 10.3% during the first quarter. The Manufacturers Life Insurance Company now owns 874,566 shares of the company’s stock valued at $26,158,000 after acquiring an additional 81,568 shares during the period.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare and household cleaning products in North America, Australia, and internationally. It operates in three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning.

See Also: How does a security become overbought?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Prestige Consumer Healthcare (NYSE:PBH)

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.